• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新辅助化疗和辅助化疗在胰腺癌中的作用

The Role of Neoadjuvant and Adjuvant Chemotherapy in Pancreatic Cancer.

作者信息

K Govind Babu, Koyyala Venkata Pradeep Babu

机构信息

HCG Hospitals St. Johns Medical College and Hospital, Bangalore, Karnataka India.

Department of Medical Oncology, Shankara Cancer and Research Institute, Tezpur, Assam India.

出版信息

Indian J Surg Oncol. 2024 May;15(Suppl 2):315-321. doi: 10.1007/s13193-024-01938-6. Epub 2024 Apr 26.

DOI:10.1007/s13193-024-01938-6
PMID:38818012
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11133239/
Abstract

Pancreatic cancer is an aggressive malignancy. Recurrences are very high despite high-quality surgery necessitating adjuvant therapy. The evolution of adjuvant therapy took several decades and gradually evolved from single-agent chemotherapy to multi-agent chemotherapy. The two important agents that are active in pancreatic cancer are 5-fluorouracil and gemcitabine, and with several combinations showing better results in the subsequent trials, the most recent trial PRODIGE 24 shows a median survival of 54.4 months. The role of neoadjuvant therapy is still evolving in resectable cancers. The role of adjuvant radiotherapy is not well defined due to controversial results from historical trials.

摘要

胰腺癌是一种侵袭性恶性肿瘤。尽管高质量手术之后仍需要辅助治疗，但复发率依然很高。辅助治疗的发展历经数十年，逐渐从单药化疗发展到多药化疗。在胰腺癌治疗中有效的两种重要药物是5-氟尿嘧啶和吉西他滨，随后的多项试验表明几种联合用药方案效果更佳，最新的PRODIGE 24试验显示中位生存期为54.4个月。新辅助治疗在可切除癌症中的作用仍在不断演变。由于既往试验结果存在争议，辅助放疗的作用尚不明确。

相似文献

1
The Role of Neoadjuvant and Adjuvant Chemotherapy in Pancreatic Cancer.新辅助化疗和辅助化疗在胰腺癌中的作用
Indian J Surg Oncol. 2024 May;15(Suppl 2):315-321. doi: 10.1007/s13193-024-01938-6. Epub 2024 Apr 26.
2
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial.总新辅助 FOLFIRINOX 对比新辅助吉西他滨为基础的放化疗和辅助吉西他滨治疗可切除和交界可切除胰腺癌（PREOPANC-2 试验）：一项全国多中心随机对照试验的研究方案。
BMC Cancer. 2021 Mar 23;21(1):300. doi: 10.1186/s12885-021-08031-z.
3
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较（NORPACT-1）：一项多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.
4
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.新辅助治疗加辅助治疗或仅辅助纳武利尤单抗联合吉西他滨治疗可切除胰腺癌- NEONAX 试验（AIO-PAK-0313），AIO 胰腺癌组的一项前瞻性、随机、对照、II 期研究。
BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y.
5
Efficacy of Neoadjuvant Radiotherapy After Chemotherapy and the Optimal Interval from Radiotherapy to Surgery for Borderline Resectable and Resectable Pancreatic Cancer.化疗后新辅助放疗的疗效以及边缘可切除和可切除胰腺癌放疗至手术的最佳间隔时间
Ann Surg Oncol. 2025 Apr;32(4):2819-2829. doi: 10.1245/s10434-024-16743-2. Epub 2025 Jan 14.
6
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).可切除胰腺癌中辅助吉西他滨与新辅助吉西他滨/奥沙利铂加辅助吉西他滨的比较：一项随机多中心 III 期研究（NEOPAC 研究）。
BMC Cancer. 2011 Aug 10;11:346. doi: 10.1186/1471-2407-11-346.
7
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.在可切除边缘的胰腺癌患者中，即刻手术与短程新辅助吉西他滨联合卡培他滨、FOLFIRINOX或放化疗的比较（ESPAC5）：一项四臂、多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12.
8
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.可切除胰腺腺癌的辅助和新辅助治疗
Chin Clin Oncol. 2017 Jun;6(3):26. doi: 10.21037/cco.2017.06.23.
9
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.新辅助 FOLFIRINOX 治疗后行切除术的胰腺癌患者辅助化疗的评价。
JAMA Oncol. 2020 Nov 1;6(11):1733-1740. doi: 10.1001/jamaoncol.2020.3537.
10
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.围手术期或仅辅助使用吉西他滨联合白蛋白结合型紫杉醇治疗可切除胰腺癌（NEONAX）——AIO胰腺癌组的一项随机II期试验
Ann Oncol. 2023 Jan;34(1):91-100. doi: 10.1016/j.annonc.2022.09.161. Epub 2022 Oct 7.

本文引用的文献

1
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.NALIRIFOX 对比 nab-紫杉醇和吉西他滨用于治疗初治转移性胰腺导管腺癌（NAPOLI 3）：一项随机、开放标签、3 期临床试验。
Lancet. 2023 Oct 7;402(10409):1272-1281. doi: 10.1016/S0140-6736(23)01366-1. Epub 2023 Sep 11.
2
Preclinical development of non-viral gene therapy for patients with advanced pancreatic cancer.晚期胰腺癌患者非病毒基因治疗的临床前开发
Mol Ther Methods Clin Dev. 2023 Mar 16;29:162-172. doi: 10.1016/j.omtm.2023.03.005. eCollection 2023 Jun 8.
3
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.围手术期或仅辅助使用吉西他滨联合白蛋白结合型紫杉醇治疗可切除胰腺癌（NEONAX）——AIO胰腺癌组的一项随机II期试验
Ann Oncol. 2023 Jan;34(1):91-100. doi: 10.1016/j.annonc.2022.09.161. Epub 2022 Oct 7.
4
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.可切除胰腺腺癌围手术期化疗的疗效：一项 2 期随机临床试验。
JAMA Oncol. 2021 Mar 1;7(3):421-427. doi: 10.1001/jamaoncol.2020.7328.
5
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).吉西他滨与S-1新辅助化疗对比直接手术治疗可切除胰腺癌的随机II/III期试验（Prep-02/JSAP05）
Jpn J Clin Oncol. 2019 Feb 1;49(2):190-194. doi: 10.1093/jjco/hyy190.
6
Surgery for Pancreatic Cancer after neoadjuvant treatment.新辅助治疗后胰腺癌的手术治疗
Ann Gastroenterol Surg. 2018 Sep 10;2(6):413-418. doi: 10.1002/ags3.12203. eCollection 2018 Nov.
7
Optimizing the outcomes of pancreatic cancer surgery.优化胰腺癌手术的结果。
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26. doi: 10.1038/s41571-018-0112-1.
8
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial.FOLFIRINOX 新辅助治疗联合个体化放化疗治疗边界可切除胰腺腺癌：一项 2 期临床试验。
JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329.
9
Therapeutic developments in pancreatic cancer: current and future perspectives.胰腺癌的治疗进展：现状与未来展望。
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348. doi: 10.1038/s41575-018-0005-x.
10
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.PET-PANC：多中心前瞻性诊断准确性和健康经济学分析研究，研究联合使用 18 氟-2-氟-2-脱氧-d-葡萄糖正电子发射断层扫描与计算机断层扫描扫描对胰腺癌的诊断和治疗的影响。
Health Technol Assess. 2018 Feb;22(7):1-114. doi: 10.3310/hta22070.